



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 49/00	A1	(11) International Publication Number: WO 94/06477 (43) International Publication Date: 31 March 1994 (31.03.94)									
<p>(21) International Application Number: PCT/GB93/01861</p> <p>(22) International Filing Date: 3 September 1993 (03.09.93)</p> <p>(30) Priority data:</p> <table border="0"> <tr> <td>9219595.7</td> <td>16 September 1992 (16.09.92)</td> <td>GB</td> </tr> <tr> <td>9220638.2</td> <td>30 September 1992 (30.09.92)</td> <td>GB</td> </tr> <tr> <td>9220639.0</td> <td>30 September 1992 (30.09.92)</td> <td>GB</td> </tr> </table> <p>(71) Applicant (for GB only): HOLMES, Michael, John [GB/GB]; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).</p> <p>(71) Applicant (for all designated States except US): NYCOMED IMAGING AS [NO/NO]; Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo 4 (NO).</p>		9219595.7	16 September 1992 (16.09.92)	GB	9220638.2	30 September 1992 (30.09.92)	GB	9220639.0	30 September 1992 (30.09.92)	GB	<p>(72) Inventors; and (75) Inventors/Applicants (for US only): KLAVENESS, Jo [NO/NO]; Midtåsen 5, N-1166 Oslo (NO). RONGVED, Pål [NO/NO]; Hovdens vei 11, N-1450 Nesoddtangen (NO). JOHANSEN, John, Henrik [NO/NO]; Vekterveien 6B, N-0681 Oslo (NO). FOSS, Per, Antonius [NO/NO]; Konventveien 3B, N-0377 Oslo (NO). HØGSET, Anders [NO/NO]; Treskeveien 32A, N-0681 Osl (NO). HVOSLEF, Anne, Marie [NO/NO]; Haldenveien 20, N-1920 Serumsand (NO).</p> <p>(74) Agents: MARSDEN, John, Christopher et al.; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).</p> <p>(81) Designated States: AU, CA, FI, JP, NO, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
9219595.7	16 September 1992 (16.09.92)	GB									
9220638.2	30 September 1992 (30.09.92)	GB									
9220639.0	30 September 1992 (30.09.92)	GB									
<p>(54) Title: IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS</p> <p>(57) Abstract</p> <p>Proteinaceous gas- or gas precursor-containing microbubble contrast agents, e.g. for use in ultrasound and/or MR imaging, in which the protein matrix is crosslinked by reaction with a bifunctional aldehyde (e.g. a dialdehyde such as glutaraldehyde or an α,β-unsaturated aldehyde such as acrolein) in an aqueous medium at substantially neutral pH exhibit improved <i>in vivo</i> and storage stabilities, particularly if the matrix is also reacted with a Schiff's base reducing agent such as a borohydride. Modification of the size distribution of such crosslinked proteinaceous gas-containing contrast agents, e.g. to reduce the mean size of the microbubbles, further enhances their stability and permits preparation of novel contrast agents having a particularly narrow microbubble size distribution.</p>											

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

- 1 -

"Improvements in or relating to contrast agents"

5 This invention relates to novel contrast agents, more particularly to new gas-containing or gas-generating contrast agents of use in diagnostic imaging.

 It is well known that ultrasonic imaging comprises a potentially valuable diagnostic tool, for example in
10 studies of the vascular system, particularly in cardiology, and of tissue microvasculature. A variety of contrast agents has been proposed to enhance the acoustic images so obtained, including suspensions of solid particles, emulsified liquid droplets, gas bubbles
15 and encapsulated gases or liquids. It is generally accepted that low density contrast agents which are easily compressible are particularly efficient in terms of the acoustic backscatter they generate, and considerable interest has therefore been shown in the
20 preparation of gas-containing and gas-generating systems as ultrasound contrast agents.

 Gas-containing contrast media are also known to be effective in magnetic resonance (MR) imaging, e.g. as susceptibility contrast agents which will act to reduce
25 MR signal intensity. Oxygen-containing contrast media also represent potentially useful paramagnetic MR contrast agents.

 Furthermore, in the field of X-ray imaging it has been observed that gases such as carbon dioxide may be
30 used as negative oral contrast agents.

 Initial studies involving free gas bubbles generated in vivo by intracardiac injection of physiologically acceptable substances have demonstrated the potential efficiency of such bubbles as contrast
35 agents in echocardiography; such techniques are severely limited in practice, however, by the short lifetime of the free bubbles. Interest has accordingly been shown

- 2 -

in methods of stabilising gas bubbles for echocardiography and other ultrasonic studies, for example using emulsifiers, oils, thickeners or sugars.

It will be appreciated that for applications in echocardiography such bubble systems should preferably not exceed 8-10 microns in diameter in order to permit free passage through the capillary beds of the pulmonary system to the left atrium and ventricular cavity, with a view to facilitating ultrasonic visualisation of the left side of the heart and myocardium following intravenous injection of the contrast agent. To provide effective visualisation of the left side of the heart such bubble systems (which will hereinafter be referred to as "microbubbles") will clearly be required to exhibit adequate stability in vivo, preferably for more than one passage of circulation.

It will likewise be apparent that preformed microbubble contrast agent systems desirably exhibit good storage stability, for example in order to permit manufacture at a central location and distribution to and storage at hospitals etc. prior to use.

One area which has attracted a substantial volume of research is the manufacture of protein-encapsulated gas microbubbles for use as ultrasound contrast agents. As described in US-A-4718433 and US-A-4774958 such agents may, for example, be prepared by sonicating a viscous protein solution to generate a microbubble system and thermally or chemically denaturing at least a part of the encapsulating protein to stabilise the microbubbles. Thermal denaturation may be effected by application of heat or simply by heat generated during sonication. Chemical denaturation is effected by reaction of the protein with formaldehyde or glutaraldehyde, e.g. in an aqueous medium at pH 4.5. A preferred proteinaceous starting material is 5% human serum albumin (HSA); its use is said to encourage the formation of small microbubbles primarily having a

- 3 -

diameter in the range 2-4 microns. Microspheres produced by this technique are said to be stable on storage for 48 hours or longer.

EP-A-0324938 describes a process for preparing an improved protein-encapsulated microbubble system of the above type. This process involves a two stage sonication procedure in which the sonicator horn is first immersed in the protein solution to generate a microbubble system and is then withdrawn to a position above but proximate to the surface of the solution to induce foaming and aerosolating thereof. This is said to produce a concentrated dispersion of microbubbles predominantly of diameters less than 10 microns, which dispersion is said to be stable for 4-8 weeks or longer on storage at ambient temperature, e.g. 20-25°C. A continuous process intended to be suitable for commercial production of such protein-encapsulated microspheres is described in EP-A-0359246.

HSA is again a preferred protein for the above procedures and may be used in solution at concentrations of, for example, 0.5-25% w/w, the use of commercially available 5% aqueous solutions or diluted versions thereof, e.g. to a concentration of 0.5-3% w/w, being convenient. HSA is used in this way to prepare the experimental product Albunex®, which comprises microspheres having air microbubble centres and insolubilised (i.e. denatured) HSA walls.

While such products exhibit a reasonable level of in vitro stability during storage, as described in the above-mentioned EP-A-0324938 and EP-A-0359246, their stability in vivo following administration to a test subject has been found to be capable of improvement. Thus, for example, Shapiro et al. in J. Am. Coll. Cardiol. 16(7) (1990), pp. 1603-1607 have reported lack of reproducible and quantifiable myocardial opacification following intravenous injections of HSA ultrasound contrast agents in humans.

- 4 -

These workers also observed a rapid decrease in left ventricular contrast intensity at the left ventricular base and apex in early systole, associated with almost total disappearance of contrast by end-systole, and suggest that this is probably due to destruction of the albumin-coated microbubbles by high left ventricular systolic pressure.

A similar observation is contained in WO 92/05806, where it is stated that the comparative rigidity of the encapsulating membranes in products according to EP-A-0324938 may lead to their rupture in the blood stream through pressure variations due to heart pulsations. This document suggests that potential ultrasound membranes may be prepared by foaming an aqueous solution of a filmogenic protein and reducing the foam bubbles to a desired size range (e.g. 0.5-10 microns, preferably 4-10 microns) by application of shear (e.g. by attrition or by sonic or ultrasonic vibration). The product may be stabilised by thermal denaturation or by reaction with a protein-reactive crosslinking agent, e.g. an aldehyde or a sulphide such as cysteine, the use of aqueous formaldehyde and aqueous glutaraldehyde being illustrated. The resulting products do not appear, however, to exhibit consistently long term storage stability unless they are freeze-dried for subsequent reconstitution with water or other physiologically acceptable liquid for injection - it will be appreciated that there are significant practical advantages in avoiding this need for reformulation prior to use.

There is thus an ongoing need for contrast agents comprising protein-encapsulated gas microbubbles or gas-generating systems which exhibit improved in vivo stability combined with good storage stability.

The present invention is based inter alia on our finding that the stability of protein-based contrast agents may be substantially enhanced if the protein is reacted with a bifunctional aldehyde capable of

- 5 -

effecting crosslinking of the protein, said reaction being effected in an aqueous medium at substantially neutral pH. More particularly we have surprisingly found that the level of stability enhancement obtainable in this way may significantly exceed that obtained using acidic aqueous formaldehyde or glutaraldehyde in accordance with prior art such as the above-mentioned US-A-4718433 and US-A-4774958, especially if the crosslinking reaction is carried out in an aqueous medium which is buffered to substantially neutral pH.

The term "substantially neutral pH" as used herein refers to the central pH region which is not markedly either acidic or basic, for example the pH range 5-9.

Thus according to one aspect of the present invention we provide contrast agents comprising microbubbles of gas or a gas precursor encapsulated in a shell of protein crosslinked by reaction in an aqueous medium at substantially neutral pH with a bifunctional aldehyde capable of effecting crosslinking of the protein.

The protein component can be any protein or derivative thereof, including polyamino acids. Albumin, gelatin and γ -globulin are representative compounds, the use of human serum albumin being preferred. Such proteins may be obtained from biological sources, for example from human or animal blood, or produced by a lower organism using recombinant technology. A typical method for preparation of human serum albumin by fermentation is described in WO 90/02808.

The encapsulating protein is advantageously at least partially denatured, e.g. as a result of thermal treatment (which may for example be directly induced by sonication), as well as being crosslinked in accordance with the invention. The contrast agents of the invention may thus conveniently be obtained by crosslinking pref rmed s nicated protein-based contrast agents, f r example sonicated albumin products such as

- 6 -

Albunex®.

Bifunctional aldehydes which may be used to stabilise the ultrasound contrast agents of the invention include dialdehydes and α,β -unsaturated aldehydes. Representative dialdehydes include aliphatic dialdehydes, e.g. containing up to 10 carbon atoms, such as glutaraldehyde, adipaldehyde and 1,8-octanedial, and substituted derivatives thereof, such as 2-hydroxy-adipaldehyde. Representative α,β -unsaturated aldehydes include α,β -unsaturated aliphatic aldehydes containing up to 10 carbon atoms, for example C_{3-8} 2-alkenals such as acrolein (i.e. 2-propenal), methacrolein (i.e. 2-methyl-2-propenal), crotonaldehyde (i.e. 2-butenal), 2-pentenal and 2-hexenal, and substituted derivatives thereof such as 3-dimethylaminoacrolein.

In accordance with an additional embodiment of the invention the contrast agents may advantageously be further stabilised by reaction with a reducing agent serving to reduce the double bond of a Schiff's base (e.g. a borohydride reagent such as sodium borohydride or sodium cyanoborohydride) as described in greater detail hereinafter.

According to a further aspect of the invention we provide a process for the preparation of a microbubble contrast agent which comprises crosslinking a protein by reaction in an aqueous medium at substantially neutral pH with a bifunctional aldehyde capable of effecting crosslinking of the protein, a gas or a gas precursor being encapsulated in said protein before, during or after said crosslinking reaction.

Any biocompatible gas may be employed in this process and in the contrast agents of the invention, for example air, nitrogen, oxygen, hydrogen, nitrous oxide, carbon dioxide, helium, argon, sulphur hexafluoride and low molecular weight optionally fluorinated hydrocarbons such as methane, acetylene or carbon tetrafluoride. The gas may be free within the microbubble or may be trapped

- 7 -

or entrained within a containing substance. The term "gas" as used herein includes any substance in gaseous form at 37°C.

Gas precursors include carbonates and bicarbonates, e.g. sodium or ammonium bicarbonate and aminomalonate esters.

For ultrasonic applications such as echocardiography, in order to permit free passage through the pulmonary system and to achieve resonance with the preferred imaging frequency of about 0.1-15 MHz, it may be convenient to prepare and use microbubbles having an average size of 0.1-10 μm , e.g. 1-7 μm . Substantially larger bubbles, e.g. with average sizes of up to 500 μm , may however be useful in other applications, for example gastrointestinal imaging or investigations of the uterus or Fallopian tubes.

Generation of the microbubble system may be effected by any convenient means, e.g. by any of the appropriate methods described in the prior art. Thus, for example, gas may be entrapped in a protein solution simply by vigorously shaking the solution in the presence of the gas, i.e. creating a gas-in-liquid emulsion, for example as described in US-A-4684479. Another well known method comprises passing the gas through a syringe into a solution of the protein. As described in US-A-3900420 a microgas emulsion may be created by using an apparatus for introducing gas rapidly into a fast-flowing liquid; a region of low pressure is thereby created in the liquid, which in this instance will be a protein solution, into which the gas is introduced and the gas-in-liquid system so obtained is pumped from the apparatus.

By using electrolysis it is possible to generate a gas to be entrapped directly in a container containing a protein solution. The electrolyte or electrolytes necessary for electrolysis may additionally help to stabilize the protein-encapsulated microbubbles. An

- 8 -

aqueous solution containing one or more electrolytes will typically generate hydrogen gas at the cathode and oxygen at the anode; on adding hydrazine, nitrogen gas may be generated at the anode. The electrodes may be
5 separated by a salt bridge. Using the Kolbe reaction, one may also generate CO₂ from carboxylic acids using electrolysis.

A preferred method of generating the gas microbubble system comprises sonication of a protein
10 solution in the presence of (e.g. under an atmosphere of) the gas to be encapsulated, for example as described in the above-mentioned US-A-4718433, US-A-4774958, EP-A-0324938 or EP-A-0359246. One advantage of such
15 sonication techniques is that they may be operated so as to effect a controlled degree of denaturation of the encapsulating protein in addition to the required microbubble generation, thereby enhancing the stability of the final product.

Crosslinking of the protein in accordance with the
20 invention is conveniently effected using a solution or suspension of the protein in water or, more preferably, in an aqueous buffer system. The aldehyde may be employed in pure liquid form or in solution in water or a water-miscible cosolvent, e.g. a lower alkanol such as
25 ethanol, for example to give a 50% solution; the amount of aldehyde used is conveniently about 2-50 equivalents relative to the protein.

The crosslinking reaction may, for example, be effected at room temperature or with heating, although
30 it may be undesirable for the reaction temperature to exceed about 60°C since this may promote unwanted and excessive denaturation of the protein. The reaction medium is advantageously subjected to very gentle agitation, for example in a rotating flask. Reaction
35 times will typically be in the range 1 minute - 24 h urs.

The cr sslinking reacti n may, for example, be

- 9 -

carried out at a pH of 5-9, preferably at a pH of 6-8 such as pH 7. Where the reaction is effected in aqueous buffer, any appropriate buffer system may in general be used, e.g. as is conventional in the art. Thus, for example, a citrate/sodium hydroxide system may be used to provide a pH of about 5 or 6, phosphate buffered saline may be used to provide a pH of about 7, a borate/hydrochloric acid system may be used to provide a pH of about 8, and a borate/potassium chloride/sodium hydroxide system may be used to provide a pH of about 9.

While we do not wish to be bound by theoretical considerations, it is believed that where an α,β -unsaturated aldehyde is employed the crosslinking reaction involves, inter alia, a rapid Michael-type addition of primary amine groups in the protein to the β -carbon atom of the α,β -double bond and a slower reaction between the aldehyde function and further protein primary amine groups leading to formation of e.g. a Schiff's base containing $-\text{CH}=\text{N}-$ linkages and/or products containing $-\text{CH}(\text{OH})-\text{NH}-$ linkages (see, for example, the findings of Sebenik et al. in Polymer 31 (1990), pp. 130-134). Crosslinking using dialdehydes is believed to proceed predominantly through formation of such $-\text{CH}=\text{N}-$ and $-\text{CH}(\text{OH})-\text{NH}-$ linkages.

As indicated above, the crosslinked protein may advantageously additionally be reacted with a reducing agent serving to reduce the double bond of a Schiff's base, such as sodium borohydride or sodium cyanoborohydride; such reducing agents are conveniently employed in an amount of 2-5 equivalents relative to the aldehyde used for crosslinking. This reaction is conveniently effected at an optionally buffered pH of 5-9, preferably pH 6-8 such as pH 7, and may, if desired, be carried out simultaneously with the crosslinking reaction; thus the reducing agent may be added to the protein solution or suspension before the aldehyde is added.

- 10 -

The crosslinking reaction and any reduction reaction are preferably effected on proteinaceous material in which a gas or a gas precursor has already been encapsulated, particularly on such materials which have undergone preliminary stabilisation as a result of controlled denaturation of the encapsulating protein. Useful protein starting materials for the crosslinking reactions thus include preformed sonicated protein-based ultrasound contrast agents, for example sonicated albumin products such as Albunex®.

Such preformed protein materials, hereinafter referred to as "microspheres", are desirably washed prior to crosslinking to remove free non-encapsulating protein which would otherwise unnecessarily participate in the crosslinking reaction. This may be effected by, for example, water-washing the microspheres 3 or 4 times, allowing the microspheres to float after each washing step and withdrawing the underlying wash water, e.g. using a pipette. A suspension of the microspheres, e.g. in water or a suitable buffer system may then be subjected to reaction with the aldehyde and, if desired, a reducing agent, e.g. in a rotating flask, and thereafter washed, e.g. with water, to remove unreacted aldehyde and any reducing agent.

The product of the crosslinking reaction may possess aldehyde groups at the surfaces of the microbubbles (see e.g. Pharmaceutical Research 9(6) (1992), p. 776 and J. Pharm. Sci. 7(12) (1982), p. 1323). Such aldehyde groups will be converted to hydroxymethyl groups when the crosslinked product is subjected to a reduction reaction. Alternatively they may be reacted with an amine, preferably used in large excess, leading to formation of a Schiff's base, which may if desired thereafter be treated with a reducing agent serving to reduce the $-CH=N-$ double bonds thereof, e.g. as hereinbefore described. Use of a bifunctional amine permits replacement of the aldehyde grouping by a

- 11 -

functional group of choice; thus, for example, reaction with an amino acid will lead to introduction of carboxyl groups, reaction with an amino alcohol will lead to introduction of hydroxyl groups and reaction with a diamine will lead to introduction of amino groups.

We have additionally found that both the in vitro and in vivo stabilities of gas-containing contrast agents according to the invention may be further enhanced if the microbubbles are subjected to size distribution modification as well as to crosslinking and to any chemical reduction reaction, the term "size reduction" being used herein to denote a reduction in the mean size of the microbubbles. Such size distribution modification may, for example, involve a reduction in the mean size of the microbubbles and/or a narrowing of the size range for the microbubbles, and may be effected before, during or, more preferably, after the crosslinking and any chemical reduction reaction. Contrast agents comprising such size distribution modified microbubbles constitute a further feature of the invention.

One size distribution modification technique which may be employed comprises application of an external pressure of gas (e.g. air or oxygen) to the microbubbles or, more preferably, to a suspension thereof, e.g. in water or buffer such as phosphate buffered saline. Thus, for example, a suspension of gas-filled microbubbles may be treated with gas at a pressure of e.g. 20-100 kPa, advantageously 30-80 kPa, preferably 60-70 kPa; the treatment may conveniently be effected at room temperature in a pressure vessel, e.g. for 30 seconds - 5 minutes, advantageously for about 1 minute.

Alternatively, gas-filled microbubbles may be size distribution modified by treatment with a liquid in which the gas content is soluble, e.g. water or buffer such as phosphate buffered saline in the case of air-

- 12 -

microbubbles in such a liquid, e.g. in a rotating flask. The extent of the size distribution modification is governed by both the volume of liquid employed relative to the gas volume of the microbubbles and the dissolved
5 gas content of the liquid, increasing as the former increases and decreasing as the latter increases; these parameters may therefore be controlled to give a desired degree of size distribution modification.

Size distribution modification such that the mean
10 volume of the microbubbles is reduced by 40-60%, e.g. by about 50%, has been found to give particularly enhanced stability, coupled with high levels of acoustic attenuation when the products are used as ultrasound contrast agents. Thus, for example, such size
15 distribution modified contrast agents of the invention have been found to give strong enhancement of both arterial and venous Doppler signals in rabbits.

Size distribution modified contrast agents according to the invention are also characterised by
20 high in vitro stability, e.g. showing no loss of contrast effect over 90 seconds in standard in vitro tests for ultrasound contrast effect.

Using such size distribution modification techniques it is possible to prepare crosslinked
25 proteinaceous contrast agents in which a substantial majority, e.g. at least 85%, preferably at least 90%, of the microbubbles have sizes up to $4\mu\text{m}$, the remainder having sizes in the range $4\text{-}10\mu\text{m}$; this may be compared with, for example, the contrast agent exemplified in US-
30 A-4718433, where approximately 20% of the microbubbles have sizes exceeding $4\mu\text{m}$. Crosslinked protein-encapsulated gas microbubble contrast agents having such a size distribution are novel products which are particularly useful in, for example, ultrasound
35 techniques such as echocardiography and constitute a further feature of the invention. They may be prepared from crosslinked protein-based microbubble-containing

- 13 -

contrast agents other than those stabilised by crosslinking with bifunctional aldehydes in accordance with the present invention, for example from biodegradably crosslinked protein-encapsulated
5 microbubble contrast agents such as are described in WO 92/17213.

In general the number and size distribution of products prepared in accordance with the invention may be determined by e.g. Coulter counter analysis. With
10 this information standardised suspensions of microspheres containing a predetermined total volume of gas per unit volume of suspension may be formulated.

The contrast agents of the invention may be used in a variety of diagnostic imaging techniques, including
15 ultrasound, MR and X-ray imaging. Their use in diagnostic ultrasonic imaging and in MR imaging, e.g. as susceptibility contrast agents, constitute preferred features of the invention.

The following non-limitative examples serve to
20 illustrate the invention. All temperatures are in °C. The number concentrations of the microspheres in the Albunex® suspensions used as starting materials were generally in the range $5-9 \times 10^8/\text{ml}$.

25 Example 1

50% Ethanolic acrolein (30 μl) was added to a suspension of water-washed Albunex® microspheres (3 ml) in sterile water in a glass vial, and the vial was gently rolled on a standard roller mixer for 4 hours.

30 The resulting microsphere suspension was characterised by Coulter counter measurements; the relative gas volume of the microspheres was calculated and the suspension was standardised by adjusting its volume to a value where the gas volume was identical to
35 that of a reference suspension of untreated Albunex® microspheres prior to echogenicity measurements being made.

- 14 -

Examples 2-6

The procedure of Example 1 was repeated except that acrolein was replaced by the aldehydes listed in the following Table:-

5

10

Example	Reagent μ l	Gas Vol. %	Reagent (50% in ethanol)
1	30	89	Acrolein
2	30	85	Crotonaldehyde
3	30	13	2-Hexenal
4	30	71	Glutaraldehyde*
5	15	33	2-Hydroxyadipaldehyde*
6	15	55	1,8-Octanedial

* 25% in H₂O

15

Example 7

20

25

50% Ethanolic acrolein (30 μ l) was added to a suspension of water-washed Albunex[®] microspheres (3 ml) in sterile water in a glass vial, and the vial was gently rolled on a standard roller mixer for 4 hours. Sodium cyanoborohydride (30 μ l from a stock solution prepared by dissolving 50 mg of reducing agent in 500 μ l of water) was added in one batch to the bottom of the vial using a micropipette, and the vial was rolled overnight.

30

The resulting microsphere suspension was characterised by Coulter counter measurements; the relative gas volume of the microspheres was calculated and the suspension was standardised by adjusting its volume to a value where the gas volume was identical to that of a reference suspension of untreated Albunex[®] microspheres prior to echogenicity measurements being made.

- 15 -

Examples 8-12

The procedure of Example 7 was repeated except that acrolein was replaced by the aldehydes listed in the following Table:-

5

Example	Reagent μ l	Reducing agent; μ l	Gas Vol. %	Reagent (50% in ethanol)
7	30	30	100	Acrolein
8	30	30	98	Crotonaldehyde
9	30	30	44	2-Hexenal
10	30	30	91	Glutaraldehyde*
11	15	15	61	2-Hydroxy- adipaldehyde*
12	15	15	59	1,8-Octanedial

* 25% in H₂O

15

Example 13

An aqueous suspension of water-washed Albunex[®] microspheres (3 ml) was allowed to stand for 1 hour in a glass vial, whereafter 2.5 ml of the infranatant liquid below the floating microspheres were withdrawn using a pipette and 2.5 ml of pH 7 phosphate buffered saline were added. The vial was gently rolled on a standard roller mixer for 5 minutes to promote resuspension of the microspheres. 50% ethanolic acrolein (30 μ l) was added to the bottom of the vial using a pipette and the vial was rolled for 4 hours. Sodium cyanoborohydride (30 μ l from a stock solution prepared by dissolving 50 mg of reducing agent in 500 μ l of water) was added and the vial was rolled overnight.

30

The resulting microsphere suspension was characterised by C ulter c unter measurements; the relative gas v lum of the microspheres was calculated and the suspension was standardised by adjusting its

- 16 -

volume to a value where the gas volume was identical to that of a reference suspension of untreated Albunex[®] micr spheres prior to echogenicity measurements being made.

5

Examples 14-21

The procedure of Example 13 was repeated except that acrolein was replaced by the aldehydes listed in the following Table:-

10

15

20

Example	Reagent μ l	Reducing agent; μ l	Gas Vol. %	Reagent (50% in ethanol)
13	30	30	71	Acrolein
14	30	30	66	Methacrolein
15	50	50	100	Crotonaldehyde
16	30	30	6	2-Pentenal
17	30	30	5	2-Hexenal
18	30	30	14	3-Dimethyl- aminoacrolein
19	30	30	71	Glutaraldehyde*
20	30	30	55	2-Hydroxy- adipaldehyde*
21	30	30	8	1,8-Octanedial

* 25% in H₂O

25

Example 22

The procedure of Example 13 was repeated except that no sodium cyanoborohydride solution was added.

Examples 23-26

30

The procedure of Example 22 was repeated except that acrolein was replaced by the aldehydes listed in

- 17 -

the following Table:-

Example	Reagent μ l	Gas Vol. %	Reagent (50% in ethanol)
22	30	80	Acrolein
23	30	83	Crotonaldehyde
24	30	67	Glutaraldehyde*
25	15	8	2-Hydroxy- adipaldehyde*
26	30	10	1,8-Octanedial

* 25% in H₂O.

The in vitro echogenicity and stability of the above standardised suspensions were determined by diluting each suspension with 7ml of Isoton II (Coulter Electronics Limited, Luton, England) having a gas content similar to that of human venous blood. The acoustic transmission of each suspension was measured as a function of time, starting immediately after dilution and using a 3.5 MHz transducer.

After signal stabilisation all the products tested showed greater echogenicity than the reference suspension of untreated Albunex[®] microspheres.

A comparative experiment was performed repeating the procedure of Example 13 but using 33% aqueous formaldehyde in place of the ethanolic acrolein. The resulting product showed minimal in vitro echogenicity after signal stabilisation.

Example 27

Albunex[®] microspheres were washed three times with pH 7 phosphate buffered saline and were resuspended in phosphate buffered saline (30 ml) in a glass vial. 25% aqueous glutaraldehyde (300 μ l) was added and the vial

- 18 -

was rolled for 20 hours at room temperature.

The crosslinked microspheres so obtained were subject d to size distribution modification by either (i) adding a saturated solution of air in phosphate buffered saline (prepared by standing phosphate buffered saline in a water bath at 37° overnight with gentle stirring to remove excess gas bubbles, and having a pO_2 of about 21 kPa) and incubating the vial on a roller for 3 hours at room temperature; (ii) adding a partially degassed solution of air in phosphate buffered saline (prepared by degassing the saturated solution from (i) for 1 hour at 37°, and having a pO_2 of about 10 kPa) and incubating the vial on a roller for 3 hours at room temperature; or (iii) placing the microsphere suspension in a pressure vessel, applying a pressure of air for 1 minute, resuspending the microspheres in phosphate buffered saline in a vial and rolling the vial for 5 minutes to give a homogeneous suspension.

The volumes of solution (relative to the volume of the microsphere suspension) and air pressures employed and the gas volume concentrations of the microspheres are detailed in the following Table:-

Method	Volume/ Pressure	Microsphere volume concentration (%)	Microsphere volume concentration corrected for dilution (%)
-	-	1.76	1.76
(i)	2 vols	0.84	1.68
(i)	5 vols	0.17	0.85
(i)	9 vols	0.08	0.72
(ii)	1.5 vols	0.85	1.28
(ii)	2 vols	0.42	0.84
(ii)	3 vols	0.14	0.42
(iii)	26 kPa	1.30	1.30
(iii)	66 kPa	0.73	0.73

- 19 -

Echogenicity measurements were made on microsphere suspensions standardised to contain uniform gas volumes. The optimum degree of size distribution modification, i.e. that which gave stable acoustic attenuation at as high a level as possible, was found to be about 50% reduction of the microsphere volume, e.g. as obtained by addition of about 5 volumes of saturated phosphate buffered saline or 2 volumes of partially degassed phosphate buffered saline or by application of an overpressure of 66 kPa of air. Addition of higher volumes of phosphate buffered saline or application of higher pressures yielded microspheres which exhibited high stability but reduced acoustic attenuation, the use of extreme volumes/ pressures leading to collapse of the microspheres and consequent loss of acoustic attenuation.

Example 28

Size distribution modified microspheres were prepared in accordance with method (iii) of Example 27, applying an air pressure of 66 kPa. The resulting microspheres were washed three times with phosphate buffered saline and concentrated by flotation/removal of the underlying solution. Physical characteristics of the microspheres (a) before size distribution modification, (b) after size distribution modification, (c) after washing and (d) after concentration are shown in the following Tables:-

- 20 -

Stage	Microsphere concentration ($10^8/\text{ml}$)	Mean diameter (μm)	Microsphere volume concentration (%)
(a)	8.59	2.99	2.75
(b)	8.75	2.41	0.96
(c)	3.01	2.50	0.35
(d)	23.6	2.64	3.16

Stage	Initial acoustic attenuation (dB/cm)	Acoustic attenuation after 90 seconds (dB/cm)
(a)	15.5	8.4
(b)	11.5	11.7
(c)	9.5	10.1
(d) ¹	15.1	15.7
(d) ²	10.0	10.4

¹ using 0.5 μl gas volume

² using 0.3 μl gas volume

Stage	Size distribution	
	0-4 μm (%)	4-10 μm (%)
(a)	79	21
(b)	95	5
(c)	94	6
(d)	92	8

Example 29

Albunex[®] microspheres were washed three times with pH 7 phosphate buffered saline and were resuspended in phosphate buffered saline (30 ml) in a glass vial. 50% ethanolic crotonaldehyde (300 μl) was added and the vial

- 21 -

was rolled for 20 hours at room temperature. Sodium cyanoborohydride (300 μ l from a stock solution prepared by dissolving 100 mg of the reducing agent in 1 ml of water) was then added and the vial was rolled for a further hour at room temperature.

The crosslinked microspheres so obtained were subjected to size distribution modification using the methods described in Example 27 and were found to give similar results to size distribution modified glutaraldehyde-crosslinked microspheres.

Example 30

Isoton II (250 ml) in a capped 500 ml flask was placed in a water bath at 37° and saturated with air overnight, with magnetic stirring. The flask was thereafter placed on a magnetic stirrer at ambient temperature and stirred at 250-300 rpm. Within 5 minutes of removing the flask from the water bath, a suspension of glutaraldehyde-crosslinked albumin microspheres prepared as described in Example 24 using 300 μ l of reagent and having a gas volume of 25% (30 ml) was injected by means of a syringe and needle through the cap into the Isoton, and stirring was continued for 4 hours. The flask was then left standing overnight to permit flotation of the microspheres. The Isoton was removed from the bottom of the flask using a syringe and needle, a further needle being placed in the cap to permit aspiration, whereafter phosphate buffered saline (15 ml) was added and the flask was rolled for 20 minutes to promote homogeneous suspension of the microspheres. The resulting suspension was characterised by Coulter counter analysis and echogenicity measurement, as shown in the following Table:-

35

- 22 -

		0-4 μ m (%)	4-10 μ m (%)	>10 μ m (%)	Initial Acoustic attenuatio n (dB/cm)	Acoustic attenua- tion after 90 seconds (dB/cm)
5	Before size distrib- ution modifi- cation	73	26.5	0.5	5.6	2.4
10	After size distrib- ution modifi- cation	89	11	0	8.9	8.9
15						

Example 31

20 The procedure of Example 30 was repeated using 50%
ethanolic aerolein (300 μ l) as the crosslinking agent to
give microspheres having a gas volume prior to size
distribution modification of 12%.

- 23 -

Claims

1. Contrast agents comprising microbubbles of gas or a gas precursor encapsulated in a shell of protein crosslinked by reaction in an aqueous medium at substantially neutral pH with a bifunctional aldehyde capable of effecting crosslinking of the protein.
2. Contrast agents as claimed in claim 1 wherein the protein is albumin, gelatin or γ -globulin.
3. Contrast agents as claimed in claim 2 wherein the protein is human serum albumin.
4. Contrast agents as claimed in any one of the preceding claims wherein the aldehyde is a dialdehyde or an α,β -unsaturated aldehyde.
5. Contrast agents as claimed in claim 4 wherein the aldehyde is selected from glutaraldehyde, adipaldehyde, 2-hydroxyadipaldehyde, 1,8-octanedial, acrolein, 3-dimethylaminoacrolein, methacrolein, crotonaldehyde, 2-pentenal and 2-hexenal.
6. Contrast agents as claimed in any of the preceding claims wherein the crosslinked protein has also been reacted with a reducing agent serving to reduce the double bond of a Schiff's base.
7. Contrast agents as claimed in any of the preceding claims comprising gas microbubbles which have been subjected to size distribution modification.
8. Contrast agents as claimed in claim 7 characterised in that they show no loss of contrast effect ver 90 seconds during in vitro monitoring f such c ntrast effect.

- 24 -

9. Contrast agents comprising microbubbles of gas encapsulated in a crosslinked protein shell characterised in that at least 85% of the microbubbles have sizes up to 4 μm and the remainder have sizes in the range 4-10 μm .
10. Contrast agents as claimed in claim 9 wherein at least 90% of the microbubbles have sizes up to 4 μm .
11. Use of a contrast agent as claimed in any of the preceding claims in diagnostic imaging.
12. Use of a contrast agent as claimed in any of claims 1 to 10 in diagnostic ultrasonic imaging.
13. Use of a contrast agent as claimed in any of claims 1 to 10 in magnetic resonance imaging.
14. A method of generating enhanced images of a human or non-human animal body which comprises administering to said body a contrast agent as claimed in any of claims 1 to 10 and generating an ultrasound or MR image of at least a part of said body.
15. A process for the preparation of a microbubble contrast agent as claimed in claim 1 which comprises crosslinking a protein by reaction in an aqueous medium at substantially neutral pH with a bifunctional aldehyde capable of effecting crosslinking of the protein, a gas or a gas precursor being encapsulated in said protein before, during or after said crosslinking reaction.
16. A process as claimed in claim 15 which comprises crosslinking preformed sonicated protein-based microspheres.

- 25 -

17. A process as claimed in claim 15 or claim 16 wherein the crosslinking is effected at a pH in the range 6-8.
- 5 18. A process as claimed in claim 17 wherein the crosslinking is effected at a pH of about 7.
19. A process as claimed in any of claims 15 to 18 wherein the crosslinking is effected in an aqueous
10 buffer system.
20. A process as claimed in claim 19 wherein the buffer is phosphate buffered saline.
- 15 21. A process as claimed in any of claims 15 to 20 wherein the crosslinked protein is also reacted with a reducing agent serving to reduce the double bond of a Schiff's base, or wherein such a reducing agent is present during the crosslinking reaction.
20
22. A process as claimed in claim 21 wherein the reducing agent is sodium borohydride or sodium cyanoborohydride.
- 25 23. A process as claimed in any of claims 15 to 22 for the preparation of a gas-containing contrast agent wherein the microbubbles are also subjected to size distribution modification.
- 30 24. A process as claimed in claim 23 wherein size distribution modification is effected after crosslinking of the protein.
- 25 25. A process as claimed in claim 23 or claim 24
35 wherein size distribution modification is effected by application of an external pressure of gas to the microbubbles or a suspension thereof.

- 26 -

26. A process as claimed in claim 23 or claim 24 wherein size distribution modification is effected by treating the microbubbles with a liquid in which the gas content thereof is soluble.

5

27. A process as claimed in any of claims 23 to 26 wherein the mean volume of the microbubbles is reduced by 40-60%.

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K49/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,Y	WO,A,92 05806 (SINETICA) 16 April 1992 cited in the application see page 4, line 3 - line 19 see page 7, paragraph 1	1-27
Y	CHEMICAL ABSTRACTS, vol. 116, no. 23, 8 June 1992, Columbus, Ohio, US; abstract no. 231235m, see abstract & ACTA PHYSIOL. SCAND. vol. 144, no. 3, 1992 pages 307 - 315 J. OESTENSEN ET AL. 'INTRAVENOUS INJECTION OF ALBUNEX MICROSPHERES CAUSES THROMBOXANE MEDIATED PULMONARY HYPERTENSION IN PIGS, BUT NOT IN MONKEYS OR RABBITS.'	1-27

-/--

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "Z" document member of the same patent family

Date of the actual completion of the international search

26 January 1994

Date of mailing of the international search report

9. 9. 92

Name and mailing address of the ISA

European Patent Office, P.O. Box 5318 Patentlaan 2
NL - 2220 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Berte, M

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 224 934 (S. B. FEINSTEIN) 10 June 1987 cited in the application & US,A,4 718 433 (FEINSTEIN) -----	1-27
X,Y	EP,A,0 441 468 (SCHERING AG.) 14 August 1991 see column 2, line 35 - line 55 see column 3, line 48 - column 4, line 3; claims -----	1-27

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9205806	16-04-92	AU-B- 635449	18-03-93
		AU-A- 8495891	28-04-92
		CA-A- 2068334	06-04-92
		EP-A- 0504340	23-09-92
		JP-T- 5502681	13-05-93

EP-A-0224934	10-06-87	US-A- 4718433	12-01-88
		AU-B- 575735	04-08-88
		AU-A- 6609786	11-06-87
		DE-A- 3683735	12-03-92
		JP-C- 1677653	13-07-92
		JP-B- 3041168	21-06-91
		JP-A- 62181033	08-08-87
US-A- 4774958	04-10-88		

US-A-4718433	12-01-88	US-A- 4572203	25-02-86
		AU-B- 575735	04-08-88
		AU-A- 6609786	11-06-87
		DE-A- 3683735	12-03-92
		EP-A, B 0224934	10-06-87
		JP-C- 1677653	13-07-92
		JP-B- 3041168	21-06-91
		JP-A- 62181033	08-08-87
		US-A- 4774958	04-10-88
		AT-B- 397034	25-01-94
		AU-B- 571863	28-04-88
		AU-A- 2576984	15-08-84
		CA-A- 1221759	12-05-87
		DE-C- 3490013	15-03-90
		DE-T- 3490013	21-02-85
		EP-A, B 0135563	03-04-85
		FR-A- 2541108	24-08-84
		GB-A, B 2143327	06-02-85
		JP-B- 2024139	28-05-90
		JP-T- 60500486	11-04-85
		NL-A- 8420041	03-12-84
		SE-B- 466634	16-03-92
		SE-A- 8404797	25-09-84
		WO-A- 8402838	02-08-84

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0441468	14-08-91	DE-A- 4004430	14-08-91
		AU-A- 7098291	17-10-91
		JP-A- 5009132	19-01-93
